Determination of ER in ovarian cancer using monoclonal antibody technology

Determination of ER in ovarian cancer using monoclonal antibody technology

The Monoclonal Antibody technology has been used in 29 cases of ovarian cancer. The immuno-enzyme-assay detected positive levels of estrogen cytoplasmatic receptor in 51.8% of the cases as well as in the nuclear (51.8%). Moreover, the ER/EIA technique screened positive levels of Total ER (ER/t) in 7...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental obstetrics & gynecology 1987, Vol.14 (3-4), p.185-187
Hauptverfasser: Nardelli, G B, Lamaina, V, Dal Pozzo, M, Onnis, G L
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antibodies, Monoclonal
Cell Nucleus - ultrastructure
Cytoplasm - ultrastructure
Cytosol - ultrastructure
Female
Humans
Immunoenzyme Techniques
Middle Aged
Ovarian Neoplasms - pathology
Ovary - pathology
Receptors, Estrogen - analysis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Monoclonal Antibody technology has been used in 29 cases of ovarian cancer. The immuno-enzyme-assay detected positive levels of estrogen cytoplasmatic receptor in 51.8% of the cases as well as in the nuclear (51.8%). Moreover, the ER/EIA technique screened positive levels of Total ER (ER/t) in 72.4% versus 65.5% obtained by DCC-method. 24.1% of the cases had negative ER/t levels observed by EIA. The monoclonal antibody anti-ER is a very interesting method for studying hormone-dependent tissue, because it uses an immunological binding to antigenic protein (receptor).
ISSN:0390-6663